[1] |
WANG Shan, XIE Bo, LIU Huimin, LI Zhihao.
Adverse event signals for celecoxib based on FAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 190-194.
|
[2] |
XIONG Weiyi, REN Jingtian.
Considerations for revision of safety information in package inserts of anti-cancer drugs in post-market phase
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 94-97.
|
[3] |
SHI Xiangfen, SUN Zhiyong, ZHANG Xufeng, LU Xiaojing, DU Shuzhang, ZHANG Xiaojian.
Whole process management of narcotic drugs and psychotropic drugs based on intelligent information management system
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 899-903.
|
[4] |
PAN Zhemin, XU Sheng, ZHENG Yi, CHEN Chenxin, LIU Yongmei, ZHANG Pengpeng, YE Xiaofei, HE Jia.
Comparison of likelihood ratio tests in post-marketing safety surveillance
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(6): 655-660.
|
[5] |
ZHENG Yujing, ZHAO Zinan, JIN Pengfei, ZHAO Fei, HU Xin, ZHANG Yatong.
Active monitoring of adverse reactions of capecitabine-induced hand-foot syndrome based on the hospital information system
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 441-443.
|
[6] |
LEI Chao, QIAO Meng, CHEN Zijia, ZHANG Qiang, XIE Yanming, WANG Zhifei.
Revision of safety information in instructions of traditional Chinese patent medicines and simple preparations
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1396-1400.
|
[7] |
JIA Jinsheng, WANG Qing, LIU Hongliang, HOU Yongfang.
Evaluation index system of MAH pharmacovigilance work
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1090-1094.
|
[8] |
SU Xinxin, ZHAO Xiaoxiao, XIE Yanming.
Real-world analysis of combined administration of elemene emulsion injection in patients with liver cancer
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 929-934.
|
[9] |
HUANG Yanli, XIE Yanming, WANG Lianxin, SUN Linxi, LIU Huan, ZHUANG Yunni.
Clinical applications of Ciwujia injection in elderly patients in the real world
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 935-939.
|
[10] |
ZHANG Hongwei, LI Yuanyuan, XIE Yanming, MA Xiaochang, WANG Lianxin, WEI Ruili, SUN Linxi, XU Hongyan, ZHUANG Yan.
The drug combination of Danshen Ligustrazine injection in the real world
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 851-856.
|
[11] |
WANG Li, WANG Xiaomo, YANG Chenlu.
Bias and control in the monitoring and evaluation of post-marketing drug using the medical big data
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 239-243.
|
[12] |
SUN Chunquan, XIE Yanming, HOU Hengyue.
Data mining of clinical characteristics and combined medications of 4 832 patients with heart failure treated with Shengmai injection
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 130-133.
|
[13] |
SUN Chunquan, XIE Yanming, HOU Hengyue.
Clinical characteristics and combined medication of Shengmai injection in the treatment of 9215 elderly patients with cardiovascular diseases
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 36-40.
|
[14] |
SHA Mingquan, Li Yiyun, WEN Baoshu.
Pharmaceutical Patent Information under the Framework of American Orange Book
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(9): 817-820.
|
[15] |
LI Lan, KONG Fanyao, ZHU Ying, SHEN Lu.
Information Exchange Mechanism of Cosmetic Safety Risks in China
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 769-771.
|